In the coming year, for which we are seeking funding, we will further validate volasertib-plus-irinotecan as a potential therapy for hepatoblastoma, continue DNA & RNA sequencing, and explore the epigenetic susceptibility of hepatoblastoma based upon the cell-of-origin.
We have developed an inexpensive, time-saving replacement for mouse drug testing using quail eggs.
First to be applied to hepatoblastoma, this technology could speed discovery and testing of new drugs for many forms of childhood and adult cancer.
We hypothesize that HAS2 and IL13RA2 turn DIPG cells into “stem-like” cells that grow quickly and invade into the cancer-promoting environment caused by HAS2.
The Plexin-Semaphorin pathway is previously unexplored as a target in sarcomas but may play a central role in the progression of the soft tissue sarcoma, rhabdomyosarcoma.
Already funded by the Trey Foote Foundation This project funds a childhood cancer research scientist to explore how resistance to chemotherapy and radiation can be
Already funded by the Alex’s Lemonade Stand Foundation Alveolar rhabdomyosarcoma is a cancer of the soft tissues. This disease often responds to chemotherapy, but in
Already funded by the National Cancer Institute (NIH) The major goal of this project is to test the hypothesis that IL4Rα blockade will prevent new
Already funded by a collective of partner family foundations! Soft tissue sarcomas are among the top 5 causes of death from childhood cancer. Until now,
We propose to study anaplasia in Wilms’ tumor at a preclinical level to discover why anaplastic disease tends to be resistant to standard therapies and to predict a rational drug combination which might be more effective and less toxic for these children.
In the coming year, for which we are seeking funding, we will further validate volasertib-plus-irinotecan as a potential therapy for hepatoblastoma, continue DNA & RNA sequencing, and explore the epigenetic susceptibility of hepatoblastoma based upon the cell-of-origin.
We have developed an inexpensive, time-saving replacement for mouse drug testing using quail eggs.
First to be applied to hepatoblastoma, this technology could speed discovery and testing of new drugs for many forms of childhood and adult cancer.
We hypothesize that HAS2 and IL13RA2 turn DIPG cells into “stem-like” cells that grow quickly and invade into the cancer-promoting environment caused by HAS2.
The Plexin-Semaphorin pathway is previously unexplored as a target in sarcomas but may play a central role in the progression of the soft tissue sarcoma, rhabdomyosarcoma.
Already funded by the Trey Foote Foundation This project funds a childhood cancer research scientist to explore how resistance to chemotherapy and radiation can be
Already funded by the Alex’s Lemonade Stand Foundation Alveolar rhabdomyosarcoma is a cancer of the soft tissues. This disease often responds to chemotherapy, but in
Already funded by the National Cancer Institute (NIH) The major goal of this project is to test the hypothesis that IL4Rα blockade will prevent new
Already funded by a collective of partner family foundations! Soft tissue sarcomas are among the top 5 causes of death from childhood cancer. Until now,
We propose to study anaplasia in Wilms’ tumor at a preclinical level to discover why anaplastic disease tends to be resistant to standard therapies and to predict a rational drug combination which might be more effective and less toxic for these children.
EIN: 46-5759569
cc-TDI is a qualified 501(c)(3) charitable organization registered with the IRS
(consult with a CPA regarding specific tax implications)
Copyright 2019 – Children’s Cancer Therapy Development Institute